Skip to Content
77 Mass Ave

Rx tester

A printed device simulates cancer treatments on biopsied tissue.
February 27, 2019
Courtesy of the researchers

A 3D-printed microfluidic device that simulates cancer treatments on biopsied tumor tissue could help clinicians assess how individual patients will respond to different drugs—before administering a single dose.

Designed by MIT and Draper researchers, the device is the size of a quarter and can be printed at low cost in about an hour. It is made of a biocompatible resin that’s commonly used to make mouth guards. While other printable resins typically kill cells quickly, this near-transparent resin supports long-term survival of biopsied tissue and prints in very high resolution.

Tumor fragments are injected into the device, whose three cylindrical “chimneys” act as ports to introduce and drain fluids, such as cancer-fighting agents and nutrients for the tissue. These chimneys also remove air bubbles that might disrupt the experiment. Clinicians can use imaging techniques to see in real time how the tumor tissue responds to different drugs.

A promising application is immuno­therapy, where certain drugs rev up a patient’s immune system to fight cancer. “You can envision a future where your doctor will have a 3D printer and can print out the devices as needed,” says co-inventor Luis Fernando Velásquez-García of the Microsystems Technology Laboratories. “You can run multiple tests in parallel and figure out what would work best with the patient’s biological makeup.”

Keep Reading

Most Popular

How Rust went from a side project to the world’s most-loved programming language

For decades, coders wrote critical systems in C and C++. Now they turn to Rust.

The inside story of how ChatGPT was built from the people who made it

Exclusive conversations that take us behind the scenes of a cultural phenomenon.

Design thinking was supposed to fix the world. Where did it go wrong?

An approach that promised to democratize design may have done the opposite.

Sam Altman invested $180 million into a company trying to delay death

Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.